Concept Life Sciences provides bioanalytical support through the entire paradigm of discovery pharmacokinetics (PK) to clinical proof of concept studies. Our team has over 150 years of combined experience in developing and customizing chromatographic methods for the quantitative determination of small and large molecules.
We provide a comprehensive range of identification and validation solutions for endogenous small molecules, DNA, RNA and protein biomarkers. With expertise in tissue analysis as well as biofluids, we will help you get the time-critical data you require to meet your specific goals whether it be a discovery project or a clinical trial.
We offer a custom, advisory approach to quickly solve your bioanalytical challenges.
Our experts deliver rapid turnaround of discovery PK and distribution studies, through non-regulatory and regulatory (GLP) Toxicokinetics (TK) support and ultimately Phase 1 and Phase 2 (GCP) clinical trials.
We source ethically approved tissue from our industry suppliers and through our trusted working relationship with Lothian NHS Research Scotland Bioresource. Associated linked-anonymized patient demographic data is also available, adding power to your study.
Our biomarker capabilities:
- 10x Genomics® Chromium™ System to deliver a single-cell RNA-sequencing readout.
- NanoString service for multiplex analysis of up to 800 RNA, DNA or protein targets.
- MSD’s MESO QuickPlex SQ120 for rapid highly-sensitive results
- Akoya Biosciences® Vectra® Polaris™ Automated Quantitative Pathology Imaging System to create high-quality fluorescent images of multiple biomarkers on a single section.
- Multi-colour flow cytometry, ELISA and Luminex
Small molecule biomarkers
Concept’s highly experienced bioanalytical team have decades of know-how in developing and validating novel chromatographic assays to detect and quantify small molecule biomarkers. These assays can be validated to the appropriate standard, ranging from scientific validations (for investigative studies) through to fully validated for pivotal studies.
Concept’s highly experienced scientific team has expertise in developing novel applications of mass spectrometry and bioanalysis to ensure appropriate techniques are used to maximize data generation and to meet our client’s timelines. These include the application of ‘adductomics’ to quantify the presence of modified nucleobases within the host genomic DNA.
Our scientific experts can leverage Next Generation Sequencing-based technologies to characterize individual cells or pooled samples and generate a wealth of genomics and transcriptomics data to drive forward your Biomarker programs.
Working consultatively with clients, we use the latest 10x Genomics® Chromium™ System to deliver a single-cell RNA-sequencing readout. We also offer a NanoString service for multiplex analysis of up to 800 RNA, DNA or protein targets.
Our expert biology team offers a variety of discovery, preclinical and clinical research services. This includes validated biomarker assays, utilizing multiplex readout technologies such as MSD’s MESO QuickPlex SQ120 for rapid highly-sensitive results and Akoya Biosciences® Vectra® Polaris™ Automated Quantitative Pathology Imaging System. This allows us to create stunning high-quality fluorescent images of multiple biomarkers on a single section. Up to nine markers (8 + DAPI) (9-plex) can be visualized at 10-40x, allowing for image analysis, quantification and phenotyping of samples.
We also offer multi-color flow cytometry, ELISA and Luminex®. Our highly experienced immunologists are able to deliver a wide range of customizable multiplex analyses of protein biomarkers. Our multiplex approaches can be used to stratify patient response to therapy, supporting our client’s specific biomarker strategy from discovery through to clinic.
For those protein biomarkers which do not have suitable reagents, our specialist bioanalytical team can also provide LC-MS/MS based support. This is delivered through either intact analysis via high-resolution accurate mass or the gold standard surrogate peptide approach via more traditional quantitative LC-MS/MS techniques.